9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Study of LY3023414 in Participants With Advanced Cancer

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Study of LY3023414 in Participants With Advanced Cancer

A Study of LY3023414 in Participants With Advanced Cancer

Estimated reading time: < 1 min

Condition: Advanced Cancer

Estimated Enrollment: 156

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Recommended Phase 2 dose,  Pharmacokinetics: Maximum concentration (Cmax),  Pharmacokinetics: Time of maximal concentration, Number of participants with tumor response

Interventions: LY3023414, Midazolam

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: April 4, 2019

Completion Date: March 13, 2020

Last  Posted Date: June 18, 2019

Location: UCLA Medical Center, Los Angeles, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT01655225

Was this article helpful?
Dislike 0